Purchase Order 75N91020P00350

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $16,362.77 on February 26, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland, with an ultimate completion date of May 31, 2020. The order procures sequencing-related services or equipment from Illumina's portfolio of genomic analysis technologies and associated support.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $12,560.00 on February 22, 2021, for a service agreement with a firm fixed price structure and no set-aside designation. Performance is located in Bethesda, Maryland, with an ultimate completion date of April 30, 2021.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $24,158.08 on October 19, 2017, with an ultimate completion date of November 19, 2018. Performance occurs at Bethesda, Maryland. The order is firm fixed price with no set-aside designation. Specific requirements are not detailed in the source material.</p>

<p>The National Cancer Institute issued a $5,100.20 delivery order to Illumina, Inc. on August 24, 2017, with an ultimate completion date of September 25, 2017.</p> <p>Place of performance is Bethesda, MD 20892. The order is priced on a firm fixed-price basis with no set-aside designation. The source does not specify the parent vehicle or the specific goods or services being delivered under this order.</p>

<p>The National Cancer Institute issued a $17,792.10 delivery order to Illumina, Inc. on January 13, 2020, for reagents and consumables.</p> <p>Place of performance is Bethesda, MD 20892. Ultimate completion date is February 12, 2020. The order is firm fixed price with no set-aside designation.</p>

<p>The National Cancer Institute issued a $5,217.50 delivery order to Illumina, Inc. on February 8, 2018, with an ultimate completion date of March 10, 2018.</p> <p>Place of performance is Bethesda, MD 20892. The order is priced on a firm fixed-price basis with no set-aside designation. The source does not identify the parent vehicle under which this delivery order was issued.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $20,198.50 in scientific equipment, effective February 9, 2021, with completion targeted March 31, 2021. Performance occurs in San Diego, California. The order is firm fixed-price with no set-aside designation.</p>

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on August 15, 2016, with a ceiling value of $24,163.80 for reagents.</p> <p>Place of performance is Bethesda, MD. The order is firm fixed price with an ultimate completion date of September 14, 2016.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $13,253.75 on November 19, 2020, for the FY26 UDO Initiative.</p> <p>Performance takes place in Rockville, Maryland. The order is firm fixed price with no set-aside designation. Ultimate completion is scheduled for November 30, 2020.</p>

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $20,381.70 firm fixed price purchase order to Illumina, Inc. for unspecified products or services. The place of performance will be in Bethesda, Maryland through September 2023. Illumina will deliver the requested items or work to support the National Cancer Institute, part of the NIH focused on cancer research, treatment, and initiatives to reduce the public health burden of cancer....